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Abstract
Purpose Our aim was to study drug interactions and dose
adjustments in patients with renal impairment in the
discharge medication of surgical inpatients and to evaluate
the strengths and limitations of clinical decision support
software (CDSS) for this task.
Methods This was a cross-sectional study involving 509
surgical patients of a primary care hospital. We developed a
customized interface for the CDSS MediQ, which we used
for automated retrospective identification of drug interac-
tions in the patients’ discharge medication. The clinical
relevance of the interactions was evaluated based on the
Zurich Interaction System (ZHIAS) that incorporates the
operational classification of drug interactions (ORCA).
Prescriptions were further analyzed for recommended dose
adjustments in patients with a glomerular filtration rate
<60 ml/min.
Results For the total of 2,729 prescriptions written for the
509 patients enrolled in the study, MediQ generated 2,558
interaction alerts and 1,849 comments. Among these were
ten “high danger” and 551 “average danger” alerts that we
reclassified according to ORCA criteria. This reclassifica-
tion resulted in ten contraindicated combinations, 77
provisionally contraindicated combinations, and 310 with
a conditional and 164 with a minimal risk of adverse
outcomes. The ZHIAS classification also provides categor-
ical information on expected adverse outcomes and
management recommendations, which are presented in
detail. We identified 56 prescriptions without a recommen-
ded dose adjustment for impaired renal function.
Conclusions CDSS identified a large number of drug
interactions in surgical discharge medication, but accord-
ing to ZHIAS criteria only a minor fraction of these
appeared to involve a substantial risk to the patient.
CDSS should therefore aim at reducing over-alerting and
improve usability in order to become more efficacious in
terms of the prevention of adverse drug events in clinical
practice.
Keywords Clinical decision support software . Dose
adjustment . Drug interactions . Surgery
Introduction
Drug interactions and resulting adverse drug events
(ADE) are important pharmacotherapeutic challenges.
They cause considerable morbidity, mortality, and costs
and have been estimated to be responsible for 1% of all
hospital admissions [1–5]. Computerized physician order
entry (CPOE) combined with clinical decision support
software (CDSS) has been proposed as a valuable tool to
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prevent critical interactions and also to guide dose
adjustment in patients with impaired renal function.
Several studies have obtained encouraging results using
this tool [6, 7], with one study demonstrating a significant
81% reduction in medication errors after the introduction
of CPOE with CDSS [8]. However, several more recent
studies concluded that commonly used CDSS suffer from
“over-alerting” and that the resulting “alert-fatigue”
among physicians is an important reason why they often
fail to effectively improve medication safety in clinical
practice [9–12]. Furthermore, the frequency of specific
critical medication problems varies between different
specialties and settings. It is our belief that the first aim
of new approaches should be a highly efficient analysis of
local safety issues, as the findings from such analyses may
subsequently support the development of targeted local
measures in order to improve pharmacotherapy. In partic-
ular, we have found that more data is needed on surgical
inpatients in order to be able to evaluate medication safety
for this population.
The study reported here therefore had two major aims.
The first was to describe and quantify medication safety
with regard to drug interactions and renal dose adjustments
in patients discharged from surgical care in a regional Swiss
hospital using a new highly efficient CDSS interface for
retrospective interaction analysis. The second was to
improve the specificity of CDSS in identifying clinically
relevant drug interactions and providing related practical
prescribing information.
Material and methods
Study design
This was a cross-sectional study involving all surgical
patients discharged between 1 January and 31 October 2009
from a primary care regional hospital, including patients
from general surgery, orthopedics, urology, otorhinolaryn-
gology, and reconstructive surgery. The only exclusion
criterion was admission to the hospital for fewer than 4
nights; patients with a shorter stay were excluded in order
to assure that the pharmacotherapy was actively managed
and well documented by the treating surgeons. The regional
ethics committee approved the study protocol, including
access to the hospital’s clinical information system for the
purposes of the study.
Pharmacotherapy at discharge, demographics, medical
diagnoses, and laboratory test results were retrospectively
retrieved for each patient from their original medical
records and the hospital’s clinical information system, and
data on all patients were stored in an anonymized master
file. The latest available value for serum creatinine before
discharge was used to estimate renal function according to
the Modification of Diet in Renal Disease (MDRD) Study–
glomerular filtration rate (GFR) formula [13]. All drugs
were then matched to their corresponding Anatomical
Therapeutic Chemical (ATC) Classification System codes,
and single drugs that contained several active ingredients
were split into their component substances and treated as
separate prescriptions for all further analyses.
The data thus obtained were analyzed for the following
outcomes of interest: (1) frequency and severity grading of
drug interactions according to the commercially available
CDSS MediQ; (2) extended classification and evaluation of
the clinical relevance of interactions identified by MediQ
according to the Zurich Interaction System (ZHIAS); (3)
compliance with recommended dose adjustments in patients
with an estimated GFR <60 ml/min based on MediQ alerts,
Aronoff’s Drug prescribing in renal failure [14], and the
manufacturers’ national prescribing information (Arzneimittel-
Kompendium der Schweiz). Figure 1 shows an overview of
the study procedures and global results.
MediQ and development of a customized interface for mass
analysis
MediQ is a commercial CDSS for use as an Internet
application (www.mediq.ch). The user manually enters
concomitantly prescribed drugs for individual patients,
and MediQ then identifies interactions and generates the
following output. The first information generated is a four-
level categorical severity grading that MediQ describes as:
3 = ”high” or “strong interaction”; 2 = ”average” or
“clinically relevant interaction”; 1=“low” or an interaction
that is “relevant in exceptional cases”; 0=“no interaction”
or additional comments. This information is also presented
in a matrix overview. Second, detailed free text information
for each interaction. Third, additional tables are generated
that present pharmacokinetic effects on metabolizing
enzymes and drug transporters as well as pharmacodynamic
effects on the central nervous system for individual
substances.
Because the manual entry of prescriptions for each
patient would not be efficient for our purposes we
developed, in collaboration with MediQ, a customized data
interface for mass analysis. This allowed us to upload one
structured text file over the Internet that contained an
anonymous study number and the corresponding ATC
codes of concomitantly prescribed drugs for each patient.
Exactly the same analyses as for the usual Internet
application were then executed on the MediQ server. The
results could subsequently be downloaded over the Internet
and imported into statistical software for further analyses.
Because MediQ’s knowledge database is continuously
updated, it should be noted here that the interaction
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analyses presented in this study were all executed in July
2010.
ZHIAS classification
ZHIAS is an extended drug interaction classification system
that was developed at our department while carrying out
this and other related studies. It features four major
dimensions plus free text fields. The first dimension uses
the well-established and documented five-level grading
according to the OpeRational ClassificAtion of drug
interactions (ORCA) criteria [15]. Briefly, ORCA’s five
operational levels are defined as follows:
Grade 1=“contraindicated combination”. The risk of
such a combination always outweighs the benefit.
Grade 2=“provisionally contraindicated”. The combi-
nation should be avoided unless an interaction is
desired or no alternative is available; monitoring may
be necessary.
Grade 3=“conditional risk”. Monitoring or alternatives
should be considered.
Grade 4=“minimal risk”. No special action is needed.
Grade 5=“no interaction”.
ZHIAS’s other three major dimensions use dichotomous
variables that relate to patient management, interaction
mechanisms, and adverse effects with an increased risk
resulting from an interaction (see Table 4). For the current
study an expert panel consisting of a surgeon (TF), two
pharmacists (OZ and AF), and a clinical pharmacologist
(SR) discussed the ZHIAS classifications of identified
Fig. 1 Overview of study
procedures and global results.
ZHIAS Zurich Interaction
System, GFR glomerular
filtration rate
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interactions until common agreement was achieved. For our
assessments we referred to original and secondary litera-
ture, including—but not limited to—Hansten and Horn’s
Drug interactions: analysis and management [16], and
Stockley’s drug interactions [17].
Data analysis
Data analysis was descriptive with presentation of results in
text, tables, and figures, and the calculation of medians,
means, and proportions as appropriate. Data management
and analyses were performed with STATA ver. 11.1 for
MacOS X (STATA Corp, College Station, TX) and SPSS
ver. 19 for Windows (SPSS, Chicago, IL).
Results
Selection and characteristics of the study population
Demographic data of 552 consecutive surgical patients
hospitalized for at least 4 nights at the Department of
Surgery were retrieved from the hospital’s electronic
information system. Thereafter, the patients’ discharge
medication was abstracted from their original medical
records, including discharge letters. Forty-three patients
were subsequently excluded because they had only one
or no prescription. The characteristics of all remaining
509 patients enrolled in the study are presented in
Table 1. The mean age of the patients was 60.4 ( median
70.7, range 8–99) years. The median number of concom-
itantly prescribed substances per patient was five (range
2–17). Table 1 also presents polypharmacy distribution
over three broad categories. The frequency of prescrip-
tions over drug classes is shown in Table 2. Nonsteroidal
anti-inflammatory drugs (NSAIDs), with paracetamol
(acetaminophen) and metamizol (dipyrone), was the most
commonly prescribed drug class, followed by antithrom-
botics and cardiovascular agents.
Identification and evaluation of drug interactions
Automated analysis using MediQ generated 2,558 interac-
tion alerts and 1,849 additional comments (Fig. 1). As
expected, the number of interaction alerts per patient
markedly increased with a higher number of concomitantly
prescribed substances (Fig. 2).
Table 3 presents the results of the automated drug
interaction analysis using MediQ along with our subsequent
reclassification of MediQ “high” and “average” danger
alerts according to ORCA criteria. Of ten combinations
considered by MediQ as involving a “high danger”
interaction, none was classified as contraindicated, and
only one was classified as provisionally contraindicated
according to ORCA criteria. Of the 551 prescriptions
considered by MediQ as involving an “average danger”,
ten were classified as “contraindicated” and 76 as “provi-
sionally contraindicated”. The full evaluation of all MediQ
high and average danger interaction alerts showing all
ZHIAS dimensions is presented in Table 4. Based on our
evaluation of the management of interactions according to
ZHIAS, we concluded that 28.6% of provisionally contra-
indicated combinations and 21.9% of combinations with a
conditional risk were most likely actually desired combi-
nations with an acceptable risk–benefit ratio under the
Table 1 Characteristics of the study patients (n=509)
Characteristics n Percentage of patient cohort
Sex
Female 280 55.0
Male 229 45.0
Age category (years)
<25 20 3.9
25–44 46 9.0
45–64 138 27.1
65–84 243 47.7
≥85 62 12.2
Primary admission diagnosisa
Trauma 209 41.1
Visceral surgery 121 23.8
Orthopedics 101 19.8
Urology 22 4.3
Other 56 11.0
Admission
Elective 196 38.5
Emergency 313 61.5
Duration of hospitalization (nights)
4–6 173 34.0
7-10 152 29.9
11–30 172 33.8
>30 12 2.4
Renal function (MDRD-GFR, ml/min/1.73 m2)b
≥60 408 80.2
30–59 61 12.0
<30 or dialysis 4 0.8
Unknown 36 7.1
Number of concomitant drugs (polypharmacy)
2–4 250 49.1
5–8 173 34.0
≥9 86 16.9
MDRD-GFR, Modification of Diet in Renal Disease (MDRD) Study–
glomerular filtration rate
a Only one primary diagnosis per patient
b Last measurement before discharge
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condition that patients are appropriately monitored. Never-
theless, at the same time, in more than 70% of the
combinations there may exist alternative treatments with a
possibly more favorable risk–benefit ratio. In terms of
mechanisms, pharmacodynamic interactions were most
frequent over all ORCA classes, and increased drug effects,
particularly increased risk of bleeding, were the most
frequently encountered potential adverse consequences
resulting from interactions.
Specific interacting combinations with the highest
danger rating according to MediQ or ORCA are presented
in Table 5. MediQ classified six specific combinations as
“high danger”. In these cases, ORCA criteria emphasize
that even if the potential adverse effect may be severe, it is
possible to manage all of these interactions with appropriate
monitoring, such as for hyperkalemia or QTc prolongations,
followed by dose adjustment or stop of therapy if necessary.
In contrast, those combinations with the highest ORCA
rating may not necessarily be driven by a very high risk or
severity of an adverse event: in eight out of ten cases the
combined drugs have the same mechanism of action, and
for two, the weak evidence supporting ginkgo’s efficacy led
to our assessment of a generally unfavorable risk–benefit
ratio. Table 6 presents all specific drug interactions
classified by ZHIAS as ORCA 2 (“provisionally contra-
indicated”) and the ten most frequent specific drug
interactions classified as ORCA 3 (“conditional risk”). This
overview also shows that MediQ identified a large number
of interactions that may increase the risk of bleeding in the
studied surgical population and assigns them an “average”
risk. The multidimensional ZHIAS evaluation additionally
distinguished a more relevant bleeding risk if NSAIDs are
combined with the oral anticoagulant phenprocoumon from
a lower risk when combined with low-dose heparins and
Number of concomitant substances per patient
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interactions by different danger categories for interactions according
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Drugs Prescriptions Patients with prescriptions
n % n %
Total 2,729 100 509 100
NSAIDs including paracetamol and metamizola 712 26.1 446 87.6
Antithromboticsa 447 16.4 316 62.1
RAA system inhibitors and diuretics 280 10.3 178 35.0
Other cardiovascular agents 249 9.1 168 33.0
Gastrointestinal agents 228 8.4 204 40.1
Anti-infective agents 143 5.2 109 21.4
Dietary supplements 123 4.5 76 14.9
Opioids 82 3.0 74 14.5
Antidepressants 79 2.9 63 12.4
Antidiabetic agents 78 2.9 51 10.0
Other nervous system agents 53 1.9 44 8.6
Anxiolytics, sedatives and hypnotics 49 1.8 43 8.4
Antipsychotics 47 1.7 40 7.9
Hormones 45 1.6 41 8.1
Respiratory tract agents 37 1.4 24 4.7
Anticonvulsants 28 1.0 24 4.7
Antineoplastic and immunological agents 7 0.3 7 1.4
Other 42 1.5 39 7.7
Table 2 Discharge medication
of the study population
NSAID, Nonsteroidal anti-
inflammatory drugs
RAA, Renin–angiotensin–
aldosterone
a Low-dose acetylsalicylic acid
is included among antithrom-
botics but not under NSAIDs
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recognized that low-dose aspirin combined with phenpro-
coumon may carry a substantial risk but that this is often a
desired combination.
Dose adjustment in patients with impaired renal function
Creatinine measurements and corresponding MDRD–GFR
estimations were available for 473 (92.9%) of the 509
patients; of these, 65 patients (12.8%) had renal impairment
with a GFR <60 ml/min. Those patients received a total of
448 prescriptions for 61 distinct substances, which we
analyzed for compliance with recommended dose adjust-
ments. According to the MediQ, 26 substances accounting
for 247 prescriptions in 58 patients require dose adjustment
in the case of impaired renal function, and we identified a
failure to comply with recommended dose adjustment in 56
prescriptions for 44 patients. These are presented in Table 7,
along with our assessment of 14 prescriptions having a
major and 42 a minor risk of resulting in a related adverse
event.
Discussion
In this study, we used a customized interface with the CDSS
MediQ to retrospectively identify drug interactions and
substances that require dose adjustment for renal impair-
ment in the discharge medication of surgical inpatients.
MediQ was able to detect a very large number of (potential)
drug interactions and therefore readily demonstrates the
typical major strength as well as limitation of a CDSS.
Although this study was not designed to evaluate the
sensitivity of MediQ to detect drug interactions, our results
and the fact that its database contains about 2,000
substances and 20,000 detailed comments on related drug
interactions suggest that MediQ is indeed a highly sensitive
tool for the detection of interactions. On the other hand, our
further evaluation based on ORCA and extended ZHIAS
criteria led us to the conclusion that only a minor fraction of
alerts generated by MediQ is associated with a substantial
risk that would require medication changes. This is of
particular concern as such a low specificity with regard to
clinically relevant information can be expected to compro-
mise a physician’s compliance to use such a system in daily
practice [9–12]. In contrast, previous studies have shown
that focused information that has been pre-selected by
clinical pharmacologists and pharmacists and then clearly
communicated to treating physicians does have a long-
lasting effect on reducing the number of prescriptions for
interacting drug combinations [5]. Our own experience
from daily safety ward rounds at a university hospital are
also in agreement with this finding, but in most clinical
settings such resource intensive services are not routinely
available. Furthermore, one-dimensional, three-level “traffic
light” grading systems, such as one used by MediQ, do not
necessarily correlate with the clinical relevance of the alerts
[15, 18]. Therefore, filtering those alerts with high or
average danger ratings does not reliably solve the issue of
over-alerting. ORCA and ZHIAS consequently attempt a
different approach, i.e. to focus on clinical management and
to record additional information in a categorical format.
Although MediQ also contains additional information of
Table 3 Identification and grading of interactions by MediQ and subsequent reclassification based on ORCA criteria for MediQ level 2 and 3
alerts as part of the ZHIAS classification
Drug interaction classifications Frequency of distinct combinations in the
509 patients
Frequency of combined prescriptions in the
509 patients
n % n %
MediQ level 3 (“high”) 5 100 10 100
ORCA level 1 (“contraindicated”) 0 0 0 0
ORCA level 2 (“provisionally contraindicated”) 1 20.0 1 10.0
ORCA level 3 (“conditional risk”) 3 60.0 8 80.0
ORCA level 4 (“minimal risk”) 1 20.0 1 10.0
MediQ level 2 (“average”) 149 100 551 100
ORCA level 1 (“contraindicated”) 9 6.0 10 1.8
ORCA level 2 (“provisionally contraindicated”) 10 6.7 76 13.8
ORCA level 3 (“conditional risk”) 94 63.1 302 54.8
ORCA level 4 (“minimal risk”) 36 24.2 163 29.6
MediQ level 1 (“low”) 529 100 1,997 100
MediQ level 0 (“no interaction”) 499 100 1,849 100
ORCA, OpeRational ClassificAtion of drug interactions; ZHIAS, Zurich Interaction System
1278 Eur J Clin Pharmacol (2011) 67:1273–1282
high quality for clinical management in its free text
comments, that information is easily overseen unless one
has the time to read them all. In contrast, based on its
underlying categorical format, ZHIAS can readily display
the same information in an accordingly designed CDSS and
therefore provides the basis to present it at first glance to
Table 4 ZHIAS reclassification by ORCA categories of all 561a interactions classified by MediQ as high or average danger and their
corresponding frequencies in the study population
ZHIAS classification Frequencies in 509 patients, stratified over ORCA classes
ORCA 1
(contraindicated/risk outweighs benefit)
ORCA 2
(provisionally contraindicated)
ORCA 3
(conditional risk)
n % n % n %
Total combinations 10 100 77 100 310 100
Management
Desired 0 0 22 28.6 68 21.9
Consider alternative 10 100 55 71.4 247 79.7
Monitoring 0 0 77 100 263 84.8
Mechanismb
Pharmacokinetic 0 0 6 7.8 56 18.1
Pharnacodynamic 10 100 74 96.1 275 88.7
Adverse events with increased risk resulting from interactionsc
Increased drug effect 8 80.0 75 97.4 216 69.7
Decreased drug effect 1 10.0 1 1.3 46 14.8
Sedation (CNS) 4 40.0 5 6.5 17 5.5
Serotonin syndrome 1 10.0 1 1.3 21 6.8
Extrapyramidal symptoms 0 0 1 1.3 1 0.3
Seizures 2 20.0 1 1.3 17 5.5
CNS effects other 3 30.0 2 2.6 6 1.9
Nephrotoxicity 3 30.0 1 1.3 37 11.9
Hepatotoxicity 0 0 0 0 4 1.3
QTc prolongation 0 0 2 2.6 17 5.5
Cardiac arrhythmias 0 0 3 3.9 27 8.7
Thrombosis 0 0 0 0 6 1.9
Bleeding 4 40.0 70 90.9 171 55.2
Blood pressure up 0 0 0 0 34 11.0
Blood pressure down 1 10.0 3 3.9 22 7.1
Cardiovascular effects other 0 0 0 0 11 3.5
Hyperkalemia 1 10.0 0 0 39 12.6
Hypokalemia 0 0 0 0 9 2.9
Hyponatremia 0 0 1 1.3 5 1.6
Metabolic/endocrine effects 0 0 1 1.3 1 0.3
Gastrointestinal toxicity 2 20.0 1 1.3 8 2.6
Blood glucose up 0 0 1 1.3 2 0.6
Blood glucose down 0 0 0 0 2 0.6
Muscular toxicity 0 0 1 1.3 7 2.3
Allergy 0 0 0 0 4 1.3
Other 0 0 0 0 8 2.6
CNS, Central nervous system; QTc, QT interval corrected for heart rate
a Another 164 interactions classified by MediQ as high or average danger were reclassified into ORCA 4=minimal risk (see Table 3) and are not
shown in detail in this table
b Pharmacokinetic and Pharmacodynamic mechanisms can be involved concomitantly, and the combined total may therefore exceed 100%
c Several adverse events may result from one combination, and the combined total may therefore exceed 100%
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the treating physician. For example, for the interaction
between lisinopril and spironolactone (see Table 5), a CDSS
using ZHIAS data is able to immediately direct the
prescriber’s attention to the current serum potassium value
through one simple activated icon or even directly trigger
retrieval of the latest measurement from the hospital’s
electronic patient information system. If potassium is
indeed elevated, a warning can be displayed with a high
level of importance, whereas no further action besides
monitoring (which can also be triggered through a ZHIAS-
based system) would be required in the case of a normal
value. Furthermore, expert analysis of local results could
help to put more emphasis on interactions that have
frequently led to problems in the past in a specific setting
or are otherwise of special interest. For example, recent data
support the view that not only “typical” NSAIDs but also
metamizol can increase the risk of bleeding through
inhibition of prostaglandin synthesis, which may be of
special interest in a setting where this drug is frequently
used as an analgesic after surgery [19, 20]. Finally, our
finding that doses were apparently not adjusted for
impaired renal function in 9% of all patients and in 68%
of patients with a GFR <60 ml/min emphasizes that
automated warnings for dose adjustment should also be
part of integrated CPOE and CDSS.
Overall our results suggest that both the integration of
CDSS into the daily clinical prescription workflow as well
as their design and content require major changes in order
to effectively improve medication safety in real-life
settings. First, clinically important interaction alerts must
be automatically displayed at the time of prescription.
Second, in order to avoid over-alerting by automated CDSS
a paradigm shift may be necessary, away from a CDSS with
maximum sensitivity and towards a CDSS with the best
possible specificity for clinically relevant alerts. Third, we
must therefore increase our efforts to define clinically
relevant interactions and consider risk factors in order to
implement that information into improved CDSS. The
implementation of ZHIAS into a CDSS is one possible
solution that we explored in our study. Additional studies
will now be necessary to show whether accordingly
modified CDSS are able to actually modify prescribing
behavior and reduce adverse drug events. However, we also
conclude that any CDSS can only change prescribing
behavior if its introduction is well coordinated and
accompanied by intense personal communication with local
prescribers, further local customization, and subsequent
constant reevaluations. This process calls for a bridging
function between theoretical pharmacological knowledge
and clinical expertise, which can be a challenging new task
for clinical pharmacologists. In our case, we discussed
critical interactions and doses with the prescribing sur-
geons. Our next aim is to introduce automated alerts at the
time of prescriptions that are locally co-developed and
supported by the Department of Surgery, followed by a
systematic outcome evaluation.
Table 5 Presentation of all specific interactions with the highest severity rating according to MediQ (“high danger”)and/or ZHIAS (ORCA 1,
“contraindicated/risk always outweighs benefit”)
Drug combination Frequency in
509 patients
MediQ danger rating ZHIAS classification
ORCAa Managementb Adverse event with increased risk
n %
Lisinopril–spironolactone 5 1.0 High 3 A/M Hyperkalemia
Atorvastatin–amiodarone 2 0.4 High 3 A/M Muscle toxicity
Paroxetine–metoprolol 1 0.2 High 2 A/M Hypotension, bradycardia
Salmeterol–amiodarone 1 0.2 High 3 M QTc, arrhythmias
Melitracen–amiodarone 1 0.2 High 4 M QTc, arrhythmias
Tramadol–oxycodone 2 0.4 Average 1 A Sedation, seizures
Tramadol–buprenorphine 1 0.2 Average 1 A Sedation, seizures
Tramadol–codeine 1 0.2 Average 1 A Sedation, seizures
Tramadol–fentanyl 1 0.2 Average 1 A Sedation, seizures, serotonin syndrome
Lisinopril–irbesartan 1 0.2 Average 1 A Hyperkalemia, renal deterioration
Ginkgo biloba–phenprocoumon 1 0.2 Average 1 A Bleeding
Ginkgo biloba–clopidogrel 1 0.2 Average 1 A Bleeding
Mefenamic acid–diclofenac 1 0.2 Average 1 A GI bleeding
Mefenamic acid–ibuprofen 1 0.2 Average 1 A GI bleeding
GI, Gastrointestinal
a ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk, 4 = minimal risk
b D, Desired interaction; A,consider an available alternative; M,special monitoring recommended
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Table 6 Presentation of all specific drug interactions classified by ZHIAS as ORCA 2 (“provisionally contraindicated”), and the ten most frequent
specific drug interactions classified as ORCA 3 (“conditional risk”) in the 509 patients
Drug combination Frequency
in 509
patients
MediQ
danger
rating
ORCAa Managementb Adverse event with increased risk
n %
All combinations classified as “provisionally contraindicated” by ZHIAS
Mefenamic acid–phenprocoumon 48 9.4 Average 2 A / M Bleeding
Low dose acetylsalicylic acid–phenprocoumon 20 3.9 Average 2 D / M Bleeding
Any two benzodiazepines 2 0.4 Average 2 D / M Sedation
Metoprolol–paroxetine 1 0.2 High 2 A / M Bradycardia, hypotension
Amiodarone–nebivolol 1 0.2 Average 2 A / M Bradycardia, hypotension
Fluoxetine–citalopram 1 0.2 Average 2 A / M Hyponatremia, serotonin syndrome
Ginkgo biloba–mefenamic acid 1 0.2 Average 2 A / M Bleeding
Lithium–mefenamic acid 1 0.2 Average 2 A / M Lithium intoxication
Quetiapine–primidone 1 0.2 Average 2 A / M Sedation, loss of quetiapine efficacy
Valproic acid–phenobarbital 1 0.2 Average 2 A / M Sedation, other CNS
Ten most frequent combinations classified as “conditional risk” by ZHIAS
Mefenamic acid–dalteparin 69 13.6 Average 3 A / M Bleeding
Low dose acetylsalicylic acid–dalteparin 31 6.1 Average 3 D / M Bleeding
Metamizol–phenprocoumon 28 5.5 Average 3 A / M Bleeding
Mefenamic acid–metamizol 12 2.4 Average 3 D / M Bleeding
Mefenamic acid–lisinopril 10 2.0 Average 3 A / M Hypertension, nephrotoxicity
Diclofenac–dalteparin 8 1.6 Average 3 A / M Bleeding
Tramadol–citalopram/escitalopram 6 1.2 Average 3 A / M Serotonin syndrome
Allopurinol–amoxicillin 4 0.8 Average 3 A / M Exanthema, skin rashes
Allopurinol–phenprocoumon 4 0.8 Average 3 M Bleeding
Tramadol–quetiapine 4 0.8 Average 3 A / M Sedation, seizures
a ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk
b D, Desired interaction; A,consider an available alternative; M,special monitoring recommended
Table 7 Prescriptions without recommended dose adjustment for impaired renal function
Drug Number of prescriptions
without adjustment
GFR range
(ml/min)
Recommended maximum
dose (mg/day)
Actual dose
range (mg/day)
Risk of related
adverse event
Metformin 8 30–59 850 1,000–1,700 Major
Diclofenac 2 39–57 75 100–150 Majora
Metamizol 2 29–30 Avoid high doses 4,000 Majora
Perindopril 1 48 2 8 Majora
Rosuvastatin 1 25 Avoid 10 Major
Paracetamol 39 25–59 2,500 4,000 Minor
Atenolol 1 32 50 75 Minor
Hydrochlorothiazide 1 29 Avoid 12.5 Minor
Pregabalin 1 51 300 375 Minor
a The combination of NSAIDs, angiotensin-converting enzyme inhibitors, and preexisting renal impairment is an important risk factor for acute
renal failure, particularly if doses are not adjusted
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Conclusions
This study used a new method for the automated analysis of
pharmacotherapy with a CDSS and was therefore able to
identify drug interactions in prescription data of a selected
patient population with high efficiency. The results of such
retrospective analyses can be used for the development of
targeted measures to improve medication safety directly
where they have been identified in the past. Reclassification
of the identified interactions according to a multidimen-
sional operational interaction classification system suggests
that only a minor fraction of all identified interactions
involves a substantial risk. The implementation of such a
classification into a refined CDSS may reduce over-alerting
and consequently improve usability and therefore the
efficacy of a CDSS to prevent adverse drug events in
clinical practice. Future studies should investigate the
impact of this approach on the prevention of adverse drug
events in clinical practice.
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